Digital Solutions for Medical Affairs Teams

Effectively reach patients, HCPs, sponsors, authorities, and more

Learn More
international marketing

Digital and technology-backed workflows to assist with content, localization, and management of medical affairs content

Historically, pharmaceutical companies have organized the medical affairs department regionally instead of globally by therapeutic area. While this structure may be closer to constituents, it can produce substantial regional differences in how organizations communicate medical information to patients and other stakeholders, potentially affecting the patient and stakeholder experience.

Evolve your medical affairs communications from a regional to global, integrated model with TransPerfect Life Sciences’ tptdigital solution for Med Affairs teams.

CONTACT US ›

360 Workflow Solutions To Meet Your Medical Affairs Initiatives

  • Content creation & adaption
  • SEO best practices
  • SEM global strategies
  • Social media management & strategy
  • Multilingual video creation
tpt dig

Enhancing Communications Globally for Key Stakeholders

Attract and keep your target audience’s attention with our specialized digital division’s support

Schedule a Free Consult ›

Improve customer engagement through innovative digital solutions and interactive content

Get in Touch ›

News and Press Releases

Our industry experts have in-depth understanding of the challenges, requirements, and goals for life sciences organizations.

Regulatory Considerations for Paper COA Translations | What You Need to Know

Blog

Collecting data for a global clinical trial on paper COAs or managing a mixed-mode study that combines both paper and electronic formats means satisfying multiple regulatory bodies before a single patient enrolls. None of these entities operate on the same timeline or answer to each other. While paper instruments might seem more flexible to deploy because they don’t require electronic implementation, there are still process considerations based on the instrument’s ...

Regulatory Considerations for Paper COA Translations | What You Need to Know
Webinar

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Despite two decades of technological advancement, the debate between paper and electronic clinical outcome assessments (eCOA) remains unresolved. This webinar revisits the assumptions that continue to shape data collection strategies and examines whether current practice reflects ...
Webinar

SSCPs Are Not Labeling: Compliant AI Processes for Reduced Cost & Turnaround

In this fireside chat, TransPerfect Medical Device's President Marc Miller sits down with Dr. Keith Morel, VP of Regulatory Compliance at Qserve, to unpack a critical question facing medical device manufacturers under MDR: can you reduce the translation review process for ...
Success Stories

Top 10 Pharma Company Overhauls Global COA Program,Cutting Costs by 33% and Errors to Near Zero

Inconsistent standards, stretched timelines, and limited visibility were straining a top 10 pharma company's COA program. Discover how TransPerfect Life Sciences' centralization strategy delivered 99.7% accuracy, 40% less PM oversight, and 33% cost savings across the ...
Blog

Four Years In: What the EU Clinical Trial Regulation Has (and Hasn't) Delivered

When the EU Clinical Trial Regulation (EU CTR No 536/2014) went live for new submissions on January 31, 2022, it promised to transform how clinical trials are authorized and conducted across Europe: a single submission, one decision, and harmonized oversight. Four years in,...
Webinar

How to Make Your Academy Succeed at Global Scale—Lessons Learned on What Works and What Doesn’t

Most life sciences and MedTech companies launch a corporate academy with strong strategic intent, whether that’s executive sponsorship, a named platform, a dedicated budget, or a curriculum mapped to business goals. After launch, however, these same organizations all too often ...
Webinar

IMP Labeling Workflows That Reduce Relabeling Risk and Start-Up Delays

Investigational medicinal product (IMP) labeling sits at the heart of clinical trial supply, impacting departments across pharmaceutical organizations, from clinical operations and regulatory affairs to quality assurance and beyond. When labeling activities are managed across ...

Ready to Enhance Your Relationship with Key Stakeholders?

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.